InMed Pharmaceuticals

09/23/2025

: InMed Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

“Looking ahead, we remain focused on advancing IND-enabling studies and generating additional data that underscore INM-901’s differentiated approach. Notably, the emphasis on neuroinflammation and multi-pathway approaches appears well aligned with the themes emerging from the recent Alzheimer’s Association International Conference (“AAIC”), where leading researchers highlighted the need to move beyond amyloid and tau pathologies alone. We believe this convergence further validates our strategy and positions InMed to contribute meaningfully to the next generation of Alzheimer’s treatments.” ~Eric A. Adams, InMed Chief Executive Officer

News release here: https://ow.ly/Nyp750X0OkM

$INM

09/23/2025

: InMed Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

• Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer’s disease pathology

“Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer’s pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification.” ~Eric A. Adams, InMed Chief Executive Officer

Full news release: https://ow.ly/Z5ko50X0Oj8

$INM

09/23/2025

: InMed Reports Full Year Fiscal 2025 Financial Results & Provides Business Update

Eric A. Adams, InMed Chief Executive Officer, commented, “Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901’s potential as a small-molecule drug candidate that addresses Alzheimer’s disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer’s pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification.”

Read full news release: https://ow.ly/nzuM50X0Ogl

$INM

09/23/2025

: InMed announces financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica

Read news release here: https://ow.ly/ptKB50X0yWp

09/23/2025

: InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

• Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer’s disease pathology
• Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration
• Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026

Full news release here: https://ow.ly/npaY50X0Ob4

$INM

09/16/2025

: InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at https://ow.ly/egEn50WXJyx

Presentation and meeting details here: https://ow.ly/f78H50WXJyA

$INM

09/05/2025

InMed is in New York for the H.C. Wainwright & Co 27th Annual Global Investment Conference

InMed's conference presentation is now available on demand. Our COO, Michael Woudenberg, gives a progress update on InMed’s pipeline including recent data from the Company’s pharmaceutical program INM-901 in the treatment of Alzheimer’s.

More here: https://ow.ly/FXPZ50WQSbO

$INM

08/28/2025

In a preclinical study "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology...", hippocampal RNA expression was evaluated.

Several genes associated with inflammation, the endocannabinoid system, synaptic dysfunction and oxidative stress and apoptosis (cell death) were evaluated following treatment. In some cases, INM-901 demonstrated a dose-dependent trend towards a return to non-diseased baseline following treatment.

View the results from this study that was presented in an AAIC scientific poster: https://ow.ly/w1pm50WNfpt

InMed presented data from its INM-901 Alzheimer’s disease program at the 2025 Alzheimer’s Association International Conference held in Toronto, Canada. The latest study presented in a scientific poster entitled, “Therapeutic Potential of INM-901 in Mitigating Alzheimer’s Disease Pathology: I...

08/19/2025

In a recent long-term 5xFAD Alzheimer's preclinical study, InMed's INM-901 demonstrated a significant reduction in the biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 and NfL, suggesting a dose-dependent therapeutic effect in .

The study was presented in a scientific poster at the Alzheimer's Association International Conference.

Poster here: https://ow.ly/Jsbw50WHRCg

08/11/2025

In case you missed the conference, the Alzheimer's Association has released these key takeaways on the latest :

-Both structured and self-guided interventions focused on increasing physical activity, improving nutrition, and social challenge, and health monitoring improved in older adults at risk of cognitive decline.
-The Alzheimer’s Association released its first clinical practice guidelines on use of blood biomarker tests by specialists to assist in the of ’s disease.
-Taking a combination of common drugs to treat blood pressure, cholesterol and diabetes may slow cognitive decline, according to data from five studies.
-Lead in the atmosphere and environment may be linked to memory problems 50 years later.
-Walking and other lifestyle interventions could benefit people with the strongest known genetic risk for Alzheimer’s disease, the gene variant.
-The first results from “real world” studies of new amyloid targeting Alzheimer’s drugs confirmed findings from the late-stage clinical trials.
-Participation in the U.S. Supplemental Nutrition Assistance Program (SNAP) is linked to slower cognitive decline.
-New research gives insights into critical sex-based differences in , including how traumatic brain injuries impact women and men differently, and new understanding of cognitive symptoms for women undergoing chemotherapy for breast cancer.

Details here: https://ow.ly/36tP50WE1XE

$INM

New research results reported at AAIC 2025 are advancing what we know about risk, diagnosis and treatment of Alzheimer’s disease and other dementias.

08/05/2025

Thank you for a great conference! The recent Alzheimer's research discoveries are helping to create a stronger foundation for Alzheimer's treatment development.

InMed's AAIC poster “Therapeutic Potential of INM-901 in Mitigating Alzheimer’s Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study” is now available to view here: https://ow.ly/N8tz50WAfG0

$INM

07/28/2025

InMed Presents INM-901 Data at Alzheimer’s Association International Conference

"The latest data continues to build on mounting preclinical evidence of the potential of INM-901 as a multi-targeted treatment candidate for Alzheimer’s disease. INM-901 demonstrates a differentiated therapeutic approach in mitigating Alzheimer’s pathology and we are excited to share the results from this study with the Alzheimer’s disease community at the AAIC.”

Learn more here: https://ow.ly/tCvR50WvQ4E

$INM